Vaxart Receives $9.27M BARDA Project NextGen Award To Prepare For Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Portfolio Pulse from Benzinga Newsdesk
Vaxart, Inc. has been awarded a $9.27 million BARDA Project NextGen award to prepare for a Phase 2b clinical study of its oral pill XBB COVID-19 vaccine candidate. The study will compare the vaccine to an approved mRNA vaccine. The funding is part of a $5 billion HHS initiative to develop vaccines offering broader, more durable protection against COVID-19. Vaxart's vaccine aims to address needle-phobia and provide a cross-reactive response to various COVID variants by triggering both systemic and mucosal immune responses.
January 19, 2024 | 1:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaxart receives a $9.27 million award from BARDA to support the Phase 2b clinical study of its oral COVID-19 vaccine, which may revolutionize pandemic response and vaccination against infectious diseases.
The award from BARDA is a significant financial endorsement for Vaxart's vaccine development, indicating confidence in the potential of their oral vaccine platform. This news is likely to be viewed positively by investors, as it not only provides funding but also validates the company's research efforts. The potential for a more convenient and broadly protective vaccine could position Vaxart favorably in the market, especially if the Phase 2b study yields positive results.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100